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Salmon calcitoninThe aim of the present study was the in vivo evaluation of thiomer-coated liposomes for an oral application of
peptides. For this purpose, salmon calcitonin was chosen as a model drug and encapsulated within liposomes.
Subsequently, the drug loaded liposomes were coated with either chitosan–thioglycolic acid (CS–TGA) or an
S-protected version of the same polymer (CS–TGA–MNA), leading to an increase in the particle size of about
500 nm and an increase in the zeta potential from approximately −40 mV to a maximum value of about
+44mV, depending on the polymer. Coated liposomes were demonstrated to effectively penetrate the intestinal
mucus layer where they came in close contact with the underlying epithelium. To investigate the permeation
enhancing properties of the coated liposomes ex vivo, we monitored the transport of ﬂuoresceinisothiocyanate-
labeled salmon calcitonin (FITC-sCT) through rat small intestine. Liposomes coated with CS–TGA–MNA showed
the highest effect, leading to a 3.8-fold increase in the uptake of FITC-sCT versus the buffer control. In vivo evaluation
of the different formulationswas carried out by the oral applicationof 40μg of sCTper rat, either encapsulatedwithin
uncoated liposomes, CS–TGA-coated liposomes or CS–TGA–MNA-coated liposomes, or given as a solution serving as
negative control. The blood calcium level was monitored over a time period of 24 h. The highest reduction in the
blood calcium level, to a minimum of 65% of the initial value after 6 h, was achieved for CS–TGA–MNA-coated
liposomes. Comparing the areas above curves (AAC) of the blood calcium levels, CS–TGA–MNA-coated liposomes
led to an 8.2-fold increase compared to the free sCT solution if applied orally in the same concentration. According
to these results, liposomes coated with S-protected thiomers have demonstrated to be highly valuable carriers for
enhancing the oral bioavailability of salmon calcitonin.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Medical University of Graz,
: +43 316 4120305; fax: +43
jan.barthelmes@uibk.ac.at
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medunigraz.at (H. Mangge),
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nürch),
V. Open access under CC BY-NC-ND l1. Introduction
Biopharmaceuticals, especially peptide- and protein drugs, have
become increasingly important in modern pharmacotherapy, and the
market for these products is expected to increase further in the years to
come [1]. In particular, their oral delivery holds enormous potential as
it allows for easy and painless administration, reasonably low cost
production and generally high patient compliance. Different delivery
systems have been investigated in order to improve oral peptide delivery.
Among them are nanoparticulate systems including liposomes, self-
emulsifying systems, solid lipid nanoparticles and polymeric nano-
particles [2–5]. Other approaches to enhance the oral bioavailability of
peptides are focussing on the use of permeation enhancers [6,7], enzyme
inhibitors [8] or the targeting of apical membrane receptors [9].
Despite all these efforts, however, oral peptide delivery systems have
not yet reached their full potential. The main obstacles which need toicense.
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the systemic circulation, and the lowpermeability of such largemolecules
across the intestinal mucosa [8]. Both barriers have been addressed by a
recently developed delivery system consisting of liposomes coated with
thiolated chitosans. In different in vitro- and ex vivo studies we could
clearly show that this delivery system has the potential to protect the
drug towards the hostile gastric environment while prolonging the
residence time on intestinal mucosal membranes additionally acting as
an absorption enhancer [10,11]. So far, however, an in vivo proof-of-
principle for this promising concept is missing.
It is therefore the aim of this study to evaluate these thiomer-
coated liposomes in vivo utilizing salmon calcitonin (sCT), a well
characterized 32 amino acid peptide [12,13], as a model drug. In
order to reach this goal, sCT was encapsulated in liposomes that
were coated with the mucoadhesive polymer chitosan–thioglycolic
acid (CS–TGA). Furthermore, CS–TGA was optionally S-protected
via conjugation with 6,6′-dithionicotinamide, resulting in a chitosan–
thioglycolic acid 6-mercaptonicotinamide-conjugate (CS–TGA–MNA)
being less prone to oxidation and exhibiting higher potential to form
disulphide bonds with the mucus. As these coated liposomes have to
penetrate into the intestinal mucus layer in order to remain there for
a prolonged time and to provide a permeation enhancing effect on
the mucosa, their mucus-penetration and sCT permeation-enhancing
properties were evaluated on intestinal mucus and intestinal mucosa,
respectively. Thereafter, thiomer-coated liposomes containing sCT were
orally administered to rats, and the blood calcium levels were monitored
over 24h.
2. Materials and methods
2.1. Materials
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-
sn -glycero -3 -phosphoethanolamine -N- [4-(p-maleimidomethyl)
cyclohexane-carboxamide] (DPPE-MCC) and the ﬂuorescence-
labeled phospholipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-
N-(lissamine rhodamine B sulfonyl) (DOPE-Liss.Rhod.) were purchased
from Avanti Polar Lipids (Alabaster, AL). Chitosan–thioglycolic acid (CS–
TGA; molecular weight: 150 kDa, 660 μmol SH-groups/g polymer) and
a chitosan–thioglycolic acid 6-mercaptonicotinamide-conjugate (CS–
TGA–MNA; based on the 150 kDa CS–TGA, 380 μmol S-protected thiol
groups and 280 μmol free SH-groups/g polymer) were synthesized and
provided by the Department of Pharmaceutical Technology, University
of Innsbruck (Austria). Salmon calcitonin (sCT; 32 amino acids, molecular
weight: 3431.89 g/mol) and ﬂuoresceinisothiocyanate-labeled salmon
calcitonin (FITC-sCT; 32 amino acids, molecular weight: 3803.29 g/mol)
were synthesized and provided by piCHEM (Graz, Austria). Porcine
intestinal mucus was puriﬁed and provided by Prof. Jeffrey Pearson,
Medical School, University of Newcastle upon Tyne (United Kingdom).
The BCA protein assay kit was purchased from Thermo Scientiﬁc
(Waltham, MA, USA) and the QuantiChrom™ Calcium Assay Kit was
purchased from BioAssay Systems (Hayward, CA, USA). All other
chemicals were of reagent grade or of the best grade available and pur-
chased from Sigma-Aldrich (Vienna, Austria).
2.2. Preparation of liposomes
Liposomes were prepared by dry ﬁlm rehydration method as
described previously [10]. Brieﬂy, DPPC and DPPE-MCC were dissolved
in chloroform and mixed in a molar ratio of 3:0.3, respectively.
Subsequently, the organic solvent was evaporated in order to obtain a
lipid ﬁlm. This was dried overnight in a vacuum chamber, rehydrated
with PBS buffer (10mM phosphate, containing 150mM NaCl, pH 7.4)
to obtain a ﬁnal lipid concentration of 30 mg/ml and incubated at
50°C for 1h with repeated vortexing. Sizing of so-formedmultilamellar
liposomes was performed by 6 freeze and thaw-cycles followed byextrusion through 200 nm polycarbonate membranes (Whatman Inc.,
Clifton, NJ) with a Mini-Extruder (Avanti Polar Lipids, Alabaster, AL).
These empty liposomes were used for ex vivo permeation studies of
FITC-sCT. For in vivo studies, sCT dissolved in PBS was used for the
rehydration at a concentration of 0.4 mg/ml. Incubation and sizing
were carried out as described for empty liposomes. Free sCT was
separated from sCT loaded liposomes by size exclusion chromatography
using a Sephadex G75 column (Amersham Biosciences, Uppsala,
Sweden). The concentration of sCTwithin the liposomeswas determined
by a colorimetric assay (BCA protein assay kit, Thermo Scientiﬁc,
Waltham, MA, USA). For in vitro mucus diffusion studies, empty
liposomes were used, but with a ﬂuorescence-labeled phospholipid
incorporated within the bilayer, in a ﬁnal molar ratio of 3.3:0.01 lipid
to label. All other steps were carried out as described for empty,
unlabeled DPPC/DPPE-MCC liposomes.2.3. Coupling of thiolated chitosan
For thiomer-coated liposomes, two different polymers were used:
CS–TGA and the S-protected form of the same polymer, CS–TGA–MNA
(see Fig. 1). Both polymers were dissolved in bidistilled water in a
concentration of 2 mg/ml and added to the liposomal suspension,
which was previously diluted with PBS to a concentration of 10mg/ml.
A ﬁnal lipid to polymer weight ratio of 1:1 was maintained throughout
the study corresponding to a coupling rate of free SH-groups tomaleimide
groups of approximately 4:1. The mixture was incubated overnight at
room temperature under agitation.2.4. Particle characterization
sCT loaded liposomes were characterized by measuring their size
and zeta potential before and after polymer coupling. Size was
measured using a Zetasizer 3000HS (Malvern Instruments, Herrenberg,
Germany) after diluting the samples to a lipid concentration of about
0.03 mg/ml with bidistilled water. The polydispersity index of the
liposomal suspension is given by the width of the size distribution.
Zeta potential measurements were performed with a Zetasizer nano
ZS (Malvern Instruments, Herrenberg, Germany) after dilution of the
liposomes to a lipid concentration of 0.3mg/ml with bidistilled water.
All measurements were carried out at room temperature.2.5. In vitro mucus diffusion studies
For mucus diffusion studies about 100μl of porcine intestinal mucus
were pipetted into plastic dishes with a cube-shaped bulge (5 ×
5 × 5mm). 16 μl of a 100 μg/ml solution of either uncoated liposomes,
CS–TGA–coated liposomes, CS–TGA–MNA-coated liposomes or H2O,
the latter serving as a control, was carefully applied on top of the
mucus layer. Dishes were incubated at 37 °C and 30 rpm for 4 h and
afterwards immediately frozen at −20 °C in a cryotom (Microm,
Walldorf, Germany). The frozen samples were embedded in Tissue
Tek O.C.T T COMPOUND (VWR International, Vienna, Austria) and slices
of 8 μm thickness were cut, transferred to SuperFrost® Plus glass slides
(Thermo Scientiﬁc, Germany) and visualized immediately using the
Olympus BX51 Basic Fluorescence Microscope (Hamburg, Germany),
operating with a DP71 camera. All images were collected using an
Uplanﬂ 10× objective. For the visualization of the rhodamine-labeled
liposomes a MWIG2 ﬂuorescence ﬁlter with 520–550 nm excitation
range and an emission band pass of 580IF was used (red ﬂuorescence).
A MWIBA2 ﬁlter with 460–490 nm excitation- and 510–550 nm
emission range was used to visualize the autoﬂuorescence at the same
position of the samples (green ﬂuorescence). Overlapping ﬂuorescence
images were generated with the Olympus cell^D software.
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Fig. 1. Reaction of CS–TGA with 6,6′-dinicotinamide leads to the S-protected thiomer CS–
TGA–MNA. Both polymers were used for the coating of preformed liposomes.
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To obtain information about the permeation ability of calcitonin
through the intestinal tissue, FITC-labeled sCT was used. 200–300 g
non-fasting male Sprague–Dawley rats were sacriﬁced, their small
intestines (jejunum, ileum) removed immediately and preserved in
0.9% NaCl solution (w/v). Intestines were cut into strips of about
1.5 cm, opened longitudinally and rinsed free of luminal contents with
freshly prepared medium (138 mM NaCl, 1 mM MgSO4, 5 mM KCl,
10mM glucose and 2mM CaCl2 buffered with 10mM Hepes; pH 6.8).
Subsequently, the tissues were mounted in Ussing-type chambers
with a permeation area of 0.64 cm2. The chambers were placed in a
water bath preheated to 37°C and immediately ﬁlledwith 1mlmedium
in the acceptor compartment and 900 μl empty liposomes (lipid
concentration: 1.7 mg/ml; polymer concentration in case of coated
liposomes: 1.7 mg/ml) mixed with 100 μl of a 160 μg/ml FITC-sCT
solution in the donor compartment. To determine the permeation in
the absence of any formulation, a FITC-sCT solution in a ﬁnal
concentration of 16 μg/ml was used as control. Over an incubation
period of 3 h, 100 μl aliquots were withdrawn every 30 min from the
acceptor chamber and replaced by 100 μl of preheated medium. The
amounts of permeated drug were analyzed by ﬂuorescence
spectroscopy at an excitation wavelength of 490 nm and an emission
wavelength of 525 nm using a plate reader (Tecan Austria GmbH,
Austria). Cumulative corrections were made for previously removed
samples. Apparent permeability coefﬁcients (Papp; cm/s) for FITC-sCT
were calculated according to the following equation,
Papp ¼
Q
A  c  t
where Q is the amount of marker (μg) permeated within 3 h, A is the
diffusion area of the Ussing-type chamber (cm2), c is the initial
concentration of sCT in the donor compartment (μg/cm3) and t is the
time of the experiment (s). Transport enhancement ratios (ER) were
calculated by:
ER ¼ Papp sampleð Þ
Papp controlð Þ
:
Transepithelial electric resistance (TEER) of the intestinal tissue was
measured using an epithelial voltohmmeter (EVOM®, World Precision
Instruments, Germany) connected to a pair of adjacent electrodes.
Measurements were performed at the beginning of the study to
guarantee the integrity of intestinal tissue, and after 1, 2 and 3 h to
observe the effects of the different liposomal formulations. The TEER
measured prior to each experimentwas set as 100%, and all other values
were calculated in relation to this.2.7. Cytotoxicity
Caco-2 (human colorectal adenocarcinoma) cells were used for
cytotoxicity testing. 2×104 cells/well was seeded 24h before treatment
in 96 well plates and exposed to uncoated liposomes, CS–TGA-coated
liposomes and CS–TGA–MNA-coated liposomes suspended in DMEM
in concentrations of 0–1000 μg/ml. Exposures were performed at 37 °C
in a 95% air/5% CO2 atmosphere and two time points (4 h and 24 h)
were evaluated. Cytotoxicity was studied by formazan bioreduction
(CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay
(Promega, Vienna, Austria)), ATP content (CellTiter-Glo Luminescent
Cell Viability Assay (Promega)) and membrane integrity (CytoTox-
ONE™ Homogeneous Membrane Integrity Assay (Promega)) as pre-
viously described [14].
2.8. In vivo studies
The protocol for in vivo studies was approved by the Animal
Ethical Committee of Vienna, Austria and adheres to the Principles
of Laboratory Animal Care. In vivo studies were performed with
male Sprague–Dawley rats with an average body weight of 250 g.
Rats were randomly divided into 6 cohorts of three animals per group
and treated with different formulations as described in Section 3.5. Rats
were fasted overnight before administration and for the duration of the
experiment, but had free access to water. Before dosing the animals,
blood samples were taken from the tail vein to determine the reference
blood calcium concentration at time point zero.
In case of an oral application, aliquots (1ml) of different formulations,
or the same volume of a sCT solution in PBS,were administered through a
ﬂexible plastic stomach tube with a round tip in order to minimize
trauma. Liposomal formulations as well as the sCT solution were
standardized to a sCT concentration of 40 μg/ml before being applied.
Apart from an oral application, the sCT solution was administered
intravenously (i.v.) into the tail vein of the rat and subcutaneously (s.c.)
with a dose of 1μg and 2μg per rat, respectively.
Blood samples were collected via the tail vein after 2, 4, 6, 8, 12 and
24h of administration. After separating the blood cells from plasma, the
latter one was stored at −80 °C until further analysis. Blood calcium
concentrations were determined by using the QuantiChrom™ Calcium
Assay Kit (BioAssay Systems, Hayward, CA, USA) according to the
manufacturer's instructions.
2.9. Statistical analysis
Data are presented as mean± S.D. Data sets were compared using
Student's t-test and differences were considered signiﬁcant at p b 0.05,
very signiﬁcant at p b 0.01, and highly signiﬁcant at p b 0.001. All tests
were performed using the statistical and process management software
MINITAB 13.0.
3. Results and discussion
3.1. Particle characterization
Thiolated chitosan was linked to functionalized liposomes by
establishing a covalent thioether bond between maleimide groups
present on the head-group of DPPE-MCC and free SH-groups of the
polymer. This procedure has been intensively investigated using
different amounts of polymer [10]. At a molar ratio of 4:1 (free SH-
groups:maleimide groups) the surface of liposomes was found to be
covered with polymer, and therefore, this ratio was used in the present
study for coupling CS–TGA to the liposome resulting in a 1:1 weight
ratio of lipid to polymer. For CS–TGA–MNA-coated liposomes the
same weight ratio was used, although the amount of free SH-groups
was different, as some of the free SH-groups (380 of the originally
660 μmol SH-groups/g polymer) were protected from oxidation by
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potential measurements for all formulations used in the study were
summarized in Table 1. Coupling of the polymer to the liposome led to
an increase in size from about 175 nm to 600–700 nm, depending on
the polymer used. Furthermore, the zeta potential of the particles
increased from highly negative to highly positive values. The reason
for the smaller increase in the potential caused by CS–TGA–MNA-
coating versus CS–TGA-coating was the lower amount of free SH-
groups present on the surface of liposomes. The positive zeta potential
is regarded to be advantageous for particles intended for oral drug
delivery, as positively-charged particles were shown to adhere to the
mucus, driven by electrostatic interactions with negatively charged
sialic- and sulfonic residues of differentmucins [15,16]. These electrostatic
interactions, together with the covalent bonds, formed between thiolated
chitosans and the mucus, enhanced the mucoadhesion of coated
liposomes compared to uncoated ones.3.2. In vitro mucus diffusion studies
To study the ability of coated liposomes to penetrate the mucus,
mucus diffusion studies were carried out using porcine intestinal
mucus. Several studies showed that the use of native mucus gives
more reliable information about the in vivo interaction of particles and
mucus, than a solution of commercially available puriﬁed gastric
mucin would do [17,18]. Furthermore, porcine mucus was chosen
since its structure and molecular weight were very similar to humans
[17,19]. After incubating the mucus layer with coated- or uncoated
rhodamine-labeled liposomes, or water in case of the control, cross
sections of the frozenmucuswere visualized usingﬂuorescencemicros-
copy. From every part of the mucus, an image corresponding to the red
ﬂuorescence of the rhodamine-labeled liposomes and one corres-
ponding to the green ﬂuorescence of the mucus was taken. All images
are shown in Fig. 2. The ﬁrst three pictures show the negative control,
where only water was applied to the mucus. The picture in the middle
(merge) illustrates that all areas, which show red ﬂuorescence, also
show the same signal when visualizing green ﬂuorescence, corres-
ponding to the autoﬂuorescence of the mucus. The second three
pictures display the mucus, where uncoated liposomes, being about
175nm in size (see Table 1), were applied. Liposomes can be seen as a
diffuse, red color, being located mainly in the bottom part of the
mucus. This heterogeneous distribution of small particles in a viscous
environment was also found by Dawson et al. [20], who worked with
100- and 200nm particles in cystic ﬁbrosis sputum.
Generally, smaller particles show comparatively higher permeation
properties through gastrointestinal mucus than larger ones [21]. Apart
from size, further important factors inﬂuencing mucus diffusion
properties of particles are surface charge [18] and hydrophobicity
[17,22]. Several viruses, for example, evolved strategies in order to
penetrate the mucus barrier like (i) being small enough not to be
sterically hindered by the mucin mesh, (ii) possessing surfaces without
hydrophobicmoieties, and (iii) exhibiting a surface densely coatedwithTable 1
Composition of all liposomal suspensions used within this study and characterization concernin
surface (means± SD; n≥ 3).
Sample description Lipid compositiona Encapsulated drugb Adde
Uncoated liposomes DPPC/DPPE-MCC sCT –
CS–TGA–coated liposomes DPPC/DPPE-MCC sCT CS–T
CS–TGA–MNA-coated liposomes DPPC/DPPE-MCC sCT CS–T
a The molar ratio of DPPC to DPPE-MCC was 3:0.3 in all cases.
b Encapsulation efﬁciency: 69±12%.
c A polymer to lipid weight ratio of 1:1 was used for all formulations.positive and negative charges resulting in a neutral net charge [4,22].
Thus, particles permeate best if they are small, neutrally charged and
do not possess hydrophobic areas on their surfaces. In this context, it
was questionable, whether liposomes coated with thiolated chitosan,
being quite big, positively charged and highly mucoadhesive [10],
would be able to penetrate into the mucus at all. Nevertheless, images
for CS–TGA- and CS–TGA–MNA-coated liposomes (Fig. 2C, D) clearly
demonstrated that both are capable of penetrating the mucus. This
can be explained by the fact that mucoadhesion is not a spontaneous
but a time dependent process. As a consequence at least two mech-
anisms are taking place in parallel: On the one hand, particles penetrate
the mucus based on a concentration gradient towards the epithelium,
and on the other hand, over time, particles get immobilized in the
mucus. Hence, some thiomer-coated liposomes will stick already to
the mucus surface, but others will make it to the epithelium, where
they can interact with the mucosa. Additionally, mucoadhesive
particles, like the thiomer-coated liposomes investigated in this study,
offer in this context the advantage of a limited back diffusion when
the concentration gradient is gone. Mucus penetrating properties of
large, mucoadhesive particles was also observed by others, e.g. Cone
[22] or Wang et al. [23], who found that high concentrations of large,
mucophilic agents may alter the microstructure of the mucus, increase
its average mesh spacing and cause the formation of channels. In
agreement with this hypothesis, we suggest that aggregates of coated
liposomes interacted with the mucus, leading to a reorganization of
the mucus mesh, where smaller aggregates or single thiomer-coated
liposomes were able to intrude. Bearing in mind that the mucus layer
in this study was thicker than it would be in vivo, where it is estimated
to be below ~200 μm [4], thiomer-coated liposomes clearly possessed
the ability to diffuse into the mucus thereby getting in close contact
with the underlying epithelium.3.3. Ex vivo permeation of FITC-sCT
Previous investigations showed that liposomes coated with thiolated
chitosans exhibit permeation enhancing and efﬂux pump inhibitory
properties, using the model substances ﬂuoresceinisothiocyanate-
dextran (FD4) and rhodamine-123 (Rho-123) [11]. Now, permeation
experiments with FITC-sCT should clarify whether the delivery system
has the potential to increase the absorption of peptide drugs. To
address this question, we mixed FITC-sCT with coated and uncoated
liposomes and investigated the transport through rat small intestine
by monitoring the ﬂuorescence in the basolateral compartment over
a time period of 3h. This time frame was chosen as the average transit
time through the small intestine is about 3–4h [19]. To investigate only
the effect on the transport of the drug, excluding any inﬂuence due
to different release kinetics, FITC-sCT was not encapsulated within
liposomes, but simply mixed with different formulations before being
added to the apical compartment of the chamber.
All results displaying the cumulative transport of FITC-sCT across the
intestinal membrane, determined by increasing concentrations ofg their size, polydispersity and zeta potential after coupling the polymer to the liposomal
d polymerc Size [nm] Polydispersity index Zeta potential [mV]
174.8± 0.9 0.19± 0.01 −39.8± 2.4
GA, 150kD 709.2± 36.0 0.34± 0.05 +43.5± 1.6
GA–MNA, 150 kDa 604.8± 29.6 0.91± 0.16 +27.9± 1.1
Fig. 2. Diffusion of rhodamine-labeled liposomes through porcine intestinal mucus. Mucus
layers were incubated with uncoated liposomes (B), CS–TGA-coated liposomes (C), or CS–
TGA–MNA coated liposomes (D) and compared with a control omitting any particles (A).
Green (I) and red ﬂuorescence (II) images were merged in order to distinguish between
particles (red) and autoﬂuorescence (yellow). The mucus layer thickness is displayed by
the two dotted lines; the right side corresponds to the mucus surface, where particles have
been applied.
Fig. 3. Absorptive permeation studies of FITC-calcitonin across rat intestinal tissue. Effect
of uncoated liposomes (△) and liposomes coated with the thiolated chitosans CS–TGA
(■) and the S-protected version CS–TGA–MNA (♦) in comparison to the FITC-sCT control
(×). Indicated values are the means± SD of at least three experiments.
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Ussing-type chamber, were illustrated in Fig. 3. The resulting Papp values
and the enhancement ratios are listed in Table 2. Already in the
presence of uncoated liposomes, a slightly increased permeation of
FITC-sCT could be detected compared to the buffer control, reﬂected
by an enhancement ratio of 1.8. This might be due to interactions of
maleimide-functionalized phospholipid head-groups with glycoproteins
of the mucus, leading to a re-organization of mucins causing a change in
viscosity of the mucus and an easier penetration of the drug [24].
Nevertheless, the permeation enhancing effect of coated liposomes was
muchmore pronounced given by values of 2.7 and 3.8 for CS–TGA-coated
and CS–TGA–MNA-coated liposomes, respectively. As discussed pre-
viously, thiomers were shown to open tight junctions by reducing
oxidized glutathione on the cell surface, which, in its reduced form, is
able to inhibit the protein tyrosine phosphatase causing dephosphor-
ylation (=closing) of tight junctions [25,26]. In addition to the opening
of tight junctions, thiomers inhibit efﬂux pumps and thereby prevent
drugs from being transported back to the luminal side of the tissue once
they are absorbed from the gut [27,28]. As reported previously [29],
S-protected thiomers, like the CS–TGA–MNA used for this study, provide
better permeation enhancing- and efﬂuxpump inhibitory properties than
the corresponding, unprotected thiomer due to a higher reactivity of
S-protected thiol groups. We could conﬁrm this effect within our studies,
reﬂected by a 1.4-fold improvement of FITC-sCT permeation due to the
use of S-protected thiomers instead of conventional ones; a result that
was also found when investigating the transport of FD4 across intestinal
membranes [11].
In addition to the permeation of FITC-sCT, the TEER was monitored,
which gave direct information about the tissue integrity: If the TEERwas
too low from the start or it becomes too low during the experiment, the
tissue was most probably damaged either by mounting it in the
chamber or by taking samples with the pipette. In such a case, tissueswere discarded immediately. In addition, monitoring the TEER during
a permeation experiment provides information about opening and
closing of tight junctions. In the absence of any test compounds, only
a slight decrease in the TEER was measured over 3 h (see Fig. 4).
The addition of uncoated liposomes, CS–TGA-coated liposomes and
CS–TGA–MNA-coated liposomes resulted in a reduction of the TEER,
whereby the slightest decrease was detected for uncoated liposomes
and the highest decrease was measured for liposomes coated with
S-protected thiolated chitosan. These results reﬂect and corroborate
the ﬁndings from monitoring the drug permeation, where the
highest permeation was found in the presence of CS–TGA–MNA-coated
liposomes.
3.4. Cytotoxicity
For the assessment of cytotoxicity, the metabolic functions
according to formazan bioreduction and cellular ATP content were
determined. In addition, cell membrane integrity was assessed by the
release of lactate dehydrogenase. In all assays, using up to 1mg/ml of
thiomer-coated liposomes, no indication for cellular damage was
observed after incubation for 4h and 24h. Consistent with these results,
cellmembrane integrity, veriﬁed by the absence of lactate dehydrogenate
release, was maintained. Taken together, these results demonstrate no
cytotoxic effects in the concentration range tested.
3.5. In vivo studies
Themain objective of the presentworkwas to evaluate the potential
of thiomer-coated liposomes as oral delivery system for peptide drugs.
sCT was used as a model drug and its effect on the blood calcium level
was monitored over 24 h. As a positive control and to evaluate the
sensitivity of the analytical test method, salmon calcitonin was injected
i.v. (1μg/rat) and s.c. (2μg/rat) and compared with results obtained for
an oral application of free sCT (40 μg/rat). The mean initial serum
calcium value (“0 h”) was taken as 100% and all the following
concentrations were given as percentage of this value. As shown in
Fig. 5, both, the i.v. as well as the s.c. injection of sCT, have signiﬁcant
effects on the blood calcium level, whereas almost no effect was
detected for the orally administered sCT solution, even when a much
Table 2
Comparison of Papp values of uncoated liposomes, CS–TGA-coated liposomes and CS–TGA–
MNA-coated liposomes. Enhancement ratios result from the comparison of each test
solution with the FITC-sCT control solution. Indicated values represent the means ± SD
of at least three experiments (*p b 0.05 and **p b 0.01 compared to the buffer control).
Additionally the effect of named test compounds was tested on the TEER.
Substrate Test compound Papp × 10−5
[cm/s]
Fold increase
in Papp
Fold
decrease
in TEER
FITC-sCT Buffer 0.48±0.02 – –
Uncoated liposomes 0.86±0.34 1.8 1.2
CS–TGA-coated liposomes 1.29±0.03 2.7** 1.6*
CS–TGA–MNA-coated liposomes 1.80±0.32 3.8* 1.7*
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level (cmin) was about 40% and 27% for i.v., and s.c. injected sCT,
respectively, and was observed about 6 h after administration (tmin).
This time correlates well with ﬁndings from other research groups
who applied sCT to rats via these application routes [30,31]. All values
for cmin, tmin and the AAC (area above the curve; marks the area between
the 100%-line and the blood calcium level curve) are summarized in
Table 3.
In order to enhance the oral bioavailability of sCT, it was
encapsulated within liposomes which were applied either with or
without thiomer coating. The effects on the blood calcium level were
shown in Fig. 6 and Table 3. Comparing the AAC among different
formulations clearly demonstrates that the best result was obtained
for liposomes coated with CS–TGA–MNA, leading to an enhancement
ratio of 8.2, relative to the same amount of free sCT administered orally.
Uncoated liposomes as well as liposomes coated with conventional
thiomers also led to a considerable, but smaller increase in the AAC. In
another study where drug loaded thiomer nanoparticles were orally
administered to rats, the best results were also obtained for nanoparticles
consisting of S-protected thiomers [32]. These and our results highlight
once again the superiority of S-protected thiomers over conventional
thiomers,which is caused by the higher reactivity of S-protected thiomers
as discussed above.
Even though it is difﬁcult to compare the results of different research
groups due to differences in the calcitonin dose, the dosage form and/or
the detection method, we aimed to assess the potential of our best
formulation with respect to the outcomes of other studies [30,33,34].
Since the values for the AAC were not available, the assessment of ourFig. 4. Decrease of the transepithelial electrical resistance (TEER) after adding uncoated
liposomes (△) and liposomes coated with the thiolated chitosans CS–TGA (■) and its
S-protected form CS–TGA–MNA (♦) in comparison to FITC-sCT control (×). Indicated
values are the means± SD of at least three experiments.formulation was based on a comparison of the cmin values given. This
reveals that a calcium reduction of 65%, as achieved with CS–TGA–
MNA-coated liposomes, demonstrates an excellent result and conﬁrms
the high potential of our leading formulation.
A general question that arises when working with mucoadhesive
formulations like thiolated polymers is whether they would not stick
to the mucus within the stomach. To answer this question, we refer
to a study by Takeuchi et al., who designed liposomal formulations
for the oral administration of eel calcitonin based on mucoadhesive
chitosan-coated liposomes [35]. Within their work, they reported that
the remaining percentage of chitosan-coated liposomes in the stomach
1h after administrationwas less than 10%, which should also be true for
the formulations used herein. A reason for this observation might be
found in the mucus turnover time, which is very short in the stomach,
and so limits the diffusion of even very small mucus penetrating
particles [4,22]. Concluding from this study and our ex vivo- and
in vivo results, we propose the following scenario to happen in the
body: Thiomer-coated liposomes are stable in the gastric environment
[11] and therefore able to keep encapsulated sCT inside the core until
reaching the small intestine. When the intestinal mucus is reached,
covalent bonds are formed between SH-groups of the thiomers and
mucus glycoproteins, which lead to a prolonged residence time of the
delivery system at the site of drug absorption [10]. Our preceding
study already showed that encapsulated compounds are released
within the small intestine, triggered by simulated intestinal ﬂuid [11].
By opening tight junctions and inhibiting efﬂux pumps, thiomer-
coated liposomes, which are still present within the mucus, promote
the permeation of released calcitonin through the gut wall and into
the bloodstream, thus enhancing its oral bioavailability.4. Conclusion
Within the present study, an oral delivery system based on the
coating of liposomes with S-protected- and conventional thiolated
chitosan was evaluated. Coated liposomes were demonstrated to
effectively penetrate into the intestinal mucus layer where they come in
close contact with the underlying epithelium, and can act as permeation
enhancers. Indeed, our ex vivo studies showed that the addition of
thiomer-coated liposomes to a solution of salmon calcitonin leads to an
increased permeation of the peptide drug through rat small intestine.
The results from the in vivo study, where different formulations wereFig. 5. Effect of different application routes of sCT solution on the blood calcium level: The
applied dose per rat was either 40 μg in case of an oral application (×), 2 μg in case of a
s.c. application (□) or 1 μg for an i.v. injection (○). Indicated values are the means± SD
of three rats.
Table 3
List of all formulations used for the in vivo study and summary of the results. Each group consists of three rats and all formulations were applied in liquid form. Blood samples were taken
from the tail vain after 0, 2, 4, 6, 8, 12 and 24 h. Cmin, minimum serum calcium concentration (% of initial); tmin, time to cmin; AAC, area above the blood calcium level time curves; ER,
enhancement ratio of different oral formulations (*p b 0.05, **p b 0.01 and ***p b 0.001 compared to the sCT solution in PBS).
Groups Application route Dose [μg/rat] cmin [%] tmin [h] AAC0–24h [% * h] ER
sCT in PBS i.v. 1 60± 3 6 334± 46 –
sCT in PBS s.c. 2 73± 4 6 296± 2 –
sCT in PBS Oral 40 93± 7 6 29± 6 –
sCT encapsulated liposomes, uncoated Oral 40 85± 2 6 121± 17 4.2*
sCT encapsulated liposomes, CS–TGA coated Oral 40 82± 4 4 164± 28 5.7*
sCT encapsulated liposomes, CS–TGA–MNA coated Oral 40 65± 4 6 239± 12 8.2***
Fig. 6.Decrease in the blood calcium level as a biological response to the oral application of
sCT encapsulated within different liposomal formulations or given as a solution. sCT
containing liposomes were coated with either CS–TGA (■) or CS–TGA–MNA (♦) and
compared to uncoated, sCT loaded liposomes (△) and free sCT in solution (×). The applied
dose per rat was 40 μg sCT in all cases. Indicated values are the means±SD of three rats.
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Eapplied orally to rats, revealed a remarkable reductionof the blood calcium
level by about 35% for liposomes coated with S-protected thiomers. In
summary, our data provide a proof of concept for the use of thiomer-
coated liposomes to increase the bioavailability of orally administered
calcitonin,which is likely to be expandable tomany other peptides aswell.
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